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Systemic lupus erythematosus (SLE) is an autoimmune disorder with multiorgan
involvement; it is characterized by the production of numerous autoantibodies.
1,2
Although the pathogenesis of SLE remains unclear, autoantibodies against
autoantigen, the deposition of immune complexes, and activation of the classical
pathway complement system seem to be consequences of immune dysregulation.
2,3
Abnormal immune responses involve innate and adaptive immune systems. These
mechanisms-including hyperactive memory B cells and plasma cells, abnormal T
cell activity, monocyte abnormalities, and immunoregulation-play important roles
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Purpose: To distinguish lupus flare-up from infection in systemic lupus erythe-
matosus (SLE), we analyze the expression of circulating CD27
high plasma cells in
SLE patients with and without infection, in comparison to non-SLE patients with
infection. Materials and Methods: The percentage of circulating CD27
high plasma
cells was measured by flow cytometry in the following four groups: 36 SLE
patients without infection, 23 SLE patients with infection, eight non-SLE patients
with infection, and 26 healthy controls. Results: The frequency of CD27
high plasma
cells had a correlation with the SLE disease activity index (SLEDAI) (r = 0.866, p
< 0.05), level of anti-dsDNA (r = 0.886, p< 0.05), C3 (r = - 0.392, p< 0.05), and C4
(r = - 0.337, p < 0.05) in SLE patients without infection, but there was no correla-
tion with disease activity in SLE patients with infection. Among three groups in
particular-SLE without infection, SLE with infection, and non-SLE with infec-
tion-the percentages of CD27
high plasma cells were elevated. The percentage of
CD27
high plasma cells was higher in SLE patients with infection, when compared
to SLE patients without infection. Conclusion: The percentage of CD27
high plasma
cells is a biomarker for disease activity of SLE without infection, under correlation
with SLEDAI, anti-dsDNA, and C3 and C4 level. However, when the SLE patients
have an infection, the percentage of CD27
high plasma cells is not an adequate bio-
marker for the survey of disease activity. The percentage of CD27
high plasma cells
may serve as a potential parameter to distinguish a lupus flare-up from infection.
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INTRODUCTIONCD27
high Plasma Cells in SLE
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in the development of SLE.
1,2,4-6 In patients with SLE, hy-
peractive B cells are triggered by an autoantigen or exte-
rnal antigen, to produce numerous autoantibodies that
appear to have pathogenic consequences.
7 These autoanti-
bodies can induce damage to targeted organs and struc-
tures, including the skin, lung, brain, blood vessels, heart,
kidneys, and joints. 
Previous studies describe many new biomarkers for the
survey of SLE; these potential lupus biomarkers can be
used to survey susceptibility, diagnosis, disease activity, and
specific organ involvement.
8 The novel biomarkers to eval-
uate disease activity include serum cytokine, soluble cyto-
kine receptor, soluble cell surface molecules (CD27, CD154
and BAFF), endothelial activation markers (sVCAM,
sICAM and thrombomodulin), and cell markers (CD27
high
plasma cells and erythrocyte-C4d).
8,9 Traditional biomar-
kers for the survey of disease activity include anti-dsDNA
antibodies and serum complement levels (C3 and C4).
However, a persistently high level of anti-dsDNA antibodies
or a low level of complement (C3 and C4) is found in some
patients with SLE. Therefore, traditional biomarkers are
not always adequate in evaluating disease activity. A poten-
tial biomarker is required to survey disease activity. 
Previous studies have proposed that the frequency of
CD27
high plasma cells is high in SLE patients, and that this
metric is useful in evaluating disease activity with a signi-
ficant correlation with the systemic lupus erythematosus
disease activity index (SLEDAI) and autoantibodies.
10,11
However, the percentage of circulating CD27
high plasma
cells is also increased in non-SLE patients with bacterial
infection.
12 Distinguishing active lupus from infection is
traditionally difficult. Elevated C-reactive protein (CRP)
levels over 5 mg/dL suggest the presence of infection.
13,14
Our study aims to evaluate the percentage of circulating
CD27
high plasma cells from the peripheral blood in the SLE
patient, either with or without infection. 
Study participants
All study participants were 18 years of age or above, and
each provided written informed consent. None of the
patients were excluded from participation on the basis of
sex or ethnicity. This study was approved by the Tri-
Service General Hospital Institutional Review Board (Grant
no: 098-05-084) based on the declaration of Helsinki.
SLE patients
We analyzed 59 patients (52 women and 7 men) with
SLE, all of whom fulfilled the 1982 revised criteria of the
American College of Rheumatology, after informed con-
sent was obtained. Disease activity was evaluated in each
patient according to the SLEDAI. In laboratory studies, the
following characteristics were investigated in the patients
with SLE: CRP, blood urea nitrogen, creatinine, white
blood cell count, haemoglobulin, platelet, anti-dsDNA,
anticardiolipin IgG/IgM, anti-Sm, anti-Ro, anti-La, anti-
RNP, rheumatoid factor, and C3 and C4. The flare-up of
SLE was defined as the elevation over 3 points in SLEDAI
(compared with the patient’s previous SLEDAI) without
evidence of infection. 
Non-SLE patients with bacterial infections 
A total of eight patients (1 woman and 7 men) with acute
bacterial infection were treated with antibiotics therapy,
and blood samples were collected during the hospital
course. These infections included pneumonia, cellulitis,
urinary tract infection, and acute cholecystitis. Different
pathogens were growth from their blood culture. 
Healthy controls
The control group consisted of 26 healthy donors (18
women and 8 men). These participants were required to
complete a brief questionnaire regarding previous or cur-
rent medical conditions. 
Flow cytometric analysis
All SLE patients with or without infection and non-SLE
patients with infection were monitored for their plasma cell
number in peripheral blood during their hospital stay. In
the SLE patient with infection, after the antibiotics or con-
servative treatment, the percentage of CD27
high plasma cell
was checked again 1 to 2 months later. Briefly, 100 µL of
EDTA anti-coagulated whole blood was incubated with 20
µL fluorescein isothiocyanate (FITC)-labeled anti-CD19
and 20 µL peridinin chlorophyll protein (Per CP)-labeled
anti-CD20, in combination with 20 µL phycoerythrin (PE)-
labeled anti-CD27. Tubes were incubated for 20 min at
room temperature before lysing solution was added. Eryth-
rocytes were lysed with lysing solution for 10 min in the
dark. Blood samples were washed with phosphate-buffer-
ed saline and analyzed on a FACS-track cytometer (Becton
Dickinson). Lymphocytes were gated on the basis of for-
ward (FSC) and side scatter (SSC). A live gate was set on
the CD19+ cell population, and then we evaluated the
expression of CD27 and CD20. Frequencies of CD20-
CD27+ plasma cells were analyzed and calculated on the
same day, using CellQuest software (Becton Dickinson,
San Jose, CA, USA). 
Statistical analysis
SPSS version 15.0 software (SPSS Inc., Chicago, IL, USA)
was used to perform the statistical analyses in our study.
MATERIALS AND METHODSDifferences between median values of defined patient
groups were compared using the nonparametric Mann-
Whitney U test. A Spearman’s rank correlation was appli-
ed, to detect correlations among different study parame-
ters. Any p value less than 0.05 was considered statisti-
cally significant. 
Characteristics of the four study groups
The study population consisted of 36 SLE patients without
infection, 23 SLE patients with infection, eight non-SLE
patients with infection, and 26 healthy controls. Among
the patients with SLE, 36 patients (33 women and 3 men,
mean age 38.3 ± 2.6 years) without infection did not receive
any antibiotic therapy, and 23 patients (19 women and 4
men, mean age 39.3 ± 3.4 years) with evidence of viral or
bacterial infection received antibiotic therapy (Table 1). In
the group of non-SLE patients with infection, the bacterial
pathogens are shown in Table 2. General data vis-à-vis the
SLE patients of this study are shown in Table 3. SLE
patients without infection had significantly higher anti-
dsDNA and SLEDAI values and lower CRP and C4
values, compared to SLE patients with viral or bacterial
infections. However, the other parameter cannot distinguish
lupus flares and infection in SLE patients. 
Frequencies of peripheral CD27
high plasma cells in con-
trols, SLE patients, and non-SLE patients with infection
The frequency of peripheral CD27
high plasma cells increas-
ed in patients of SLE without infection, SLE with infection,
and non-SLE with infection, compared to healthy donors
(p < 0.05). There was a significant difference of percentage
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RESULTS
Table 1.Clinical Pathogens and Characteristics of Systemic Lupus Erythematosus Patients with Bacterial and Viral Infection
Infectious disease Pathogen
n 
Treatment
Hospital 
Clinical manifestations
(23) days
Pneumonia Streptococcus pneumonia 4 Antibiotics 7 Fever, dyspnea, productive
cough
Pseudomonas aeruginosa 1 Antibiotics 14 Fever, respiratory failure
Chlamydia pneumonia 1 Antibiotics 7 Fever, cough
Staphylococcus aureus 1 Antibiotics 14 Fever, cough
Legionella pneumonia 1 Antibiotics 14 Fever
Mycobacterium tuberculosis 1 Anti-TB drugs 9 Chronic cough
Virus infection Herpes simplex virus 2 Acyclovir 5 Fever, skin rash
Herpes zoster virus 1 Acyclovir 4 Neurological pain
Cytomegalovirus 1 Gancyclovir 5 Impaired liver function
Acute upper respiratory infection 3 Hydration 4 Fever, rhinorrhea, cough
Tonsillitis No culture report 1 Antibiotics 3 Sore throat
Urinary tract infection Escherichia coli 1 Antibiotics 7 Dysuria, fever
Acute pyelonephritis Escherichia coli 1 Antibiotics 8 Flank pain, fever
Infectious diarrhea Shigella sonnei 1 Antibiotics 9 Watery diarrhea
Salmonella enterica 1 Antibiotics 10 Fever, abdominal cramping
Necrotizing fasciitis Staphylococcus aureus 1 Debridement  41 Left calf pain, septic shock
and antibiotics
Table 2.Clinical Characteristics of Non-Systemic Lupus Erythematosus Patients with Bacterial Infection
Infectious disease Pathogen n (8)
Pneumonia Streptococcus pneumonia 2
Mycobacterium tuberculosis 1
Staphylococcus aureus 1
Pseudomonas aeruginosa 1
Cellulitis Staphylococcus aureus 1
Urinary tract infection Escherichia coli 1
Acute cholecystitis Klebsiella pneumonia 1in circulating CD27
high plasma cells, between the SLE pati-
ents with infection and those without infection (p < 0.05).
The mean percentage of circulating CD27
high plasma cells
was higher in the patients of SLE with infection and in the
group of non-SLE with infection, and there was no signi-
ficant difference between these two groups (Fig. 1). There
was no significant difference between SLE patients with bac-
terial and viral infection (41.3 ± 7.6 vs. 47.4 ± 11.8, p =
0.548). After antibiotic therapy, the percentage of CD27
high
plasma cells decreased significantly in the group of SLE
patients with infection (43.1 ± 6.3 decreased to 14.1  ± 1.2,
p < 0.05). The mean percentage of CD27
high plasma cells
and CRP levels of the study group is shown in Table 4. There
was a significant correlation between the percentage of peri-
pheral CD27
high plasma cells and disease activity, including
SLEDAI (r = 0.866, p < 0.001), anti-dsDNA (r = 0.886, p
< 0.001), C3 (r = - 0.392, p= 0.018), and C4 (r = - 0.337, p=
0.044) in the group of SLE without infection; however,
there was no statistical correlation with anti-Ro, anti-La,
anticardiolipin IgG/IgM, anti-RNP, anti-Sm, or RF. In the
SLE patients with infection, there was no correlation bet-
ween SLE disease activity and circulating CD27
high plasma
cells percentage, by SLEDAI or these autoantibodies
(Table 5) (Fig. 2). 
In humans, B cells are important to the immune system, as
they produce antibodies, act as antigen-presenting cells,
CD27
high Plasma Cells in SLE
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Table 3. Clinical Characteristics and Serological Parameters of 36 Systemic Lupus Erythematosus (SLE) 
Patients and 23 SLE Patients with Infection
SLE with flare up SLE with infection p
Age 38.3 ± 2.6 39.3 ± 3.4 NS
SLEDAI 9.5 ± 0.52 7.4 ± 0.62 < 0.05
Anti-Sm (%) 6 (16.6) 6 (26.1) NS
Anti-Ro (%) 14 (38.8) 5 (21.7) NS
Anti-La (%) 7 (19.4) 4 (17.4) NS
Anti-RNP (%) 9 (25.0) 6 (26.1) NS
Anti-cardiolipin IgG (%) 14 (38.9) 6 (26.1) NS
Anti-cardiolipin IgM (%) 2 (5.6) 0 (0) NS
Rheumatoid factor (%) 4 (11.1) 2 (8.7) NS
Anti-dsDNA (IU/mL) 95.2 ± 18.8 64.6 ± 22.7 < 0.05
C3 (mg/dL) 64.7 ± 4.64 74.4 ± 5.21 NS
C4 (mg/dL) 11.7 ± 1.13 19.8 ± 1.17 < 0.05
CRP (mg/dL) 0.7 ± 0.3 5.9 ± 1.3 < 0.05
White blood cell /µL 5,481 ± 420 5,736 ± 560 NS
Hemoglobin (g/dL) 10.4 ± 0.4 10.4 ± 0.5 NS
Platelet /µL 195,885 ± 14,211 184,086 ± 19,310 NS
BUN (mg/dL) 23.3 ± 4.1 17.2 ± 3.4 NS
Creatinine (mg/dL) 1.3 ± 0.06 1.3 ± 0.05 NS
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; CRP, C-reactive protein; BUN, Blood urea nitrogen; Cr, Creatinine; NS, not 
stignificant. 
Normal rage of anti-dsDNA (0 - 10), C3 (90 - 180), C4 (10 - 40), CRP (0 - 0.5), White blood cell (4,500 - 11,000), Hemoglobin (12 - 16), Platelet
(150,000 - 400,000), BUN (7 - 20), Cr (0.5 - 1). 
The values are presented as mean ±SEM.
Fig. 1. Comparison of the percentage of overall CD27
high plasma cells from four
groups (SLE, SLE with infection, Non-SLE with infection, healthy control). SLE,
systemic lupus erythematosus; HC,  healthy control.
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SLE SLE with infection Infectious disease HCproduce cytokines, and interact with T cells to regulate
immunity-related activities.
2,15 There are many regulatory
mechanisms-including apoptosis, receptor editing, anergy,
and clonal ignorance-underpinning B cell tolerance in
healthy individuals.
16-18 The loss of this tolerance may induce
autoreactive B cell processes, in turn possibly incurring an
autoimmune disorder. In SLE, multiple internal or external
factors increase B cell reactivity, so that it can directly result
in the production of pathologic autoantibodies and in end-
organ damage. There are generally a large number of
antibodies from the SLE patient’s blood that counter self-
antigens. Plasma cells containing surface markers of
CD19+CD20- prodigiously secrete antibodies.
11 The CD27
molecule belongs to the tumor necrosis factor receptor fa-
mily and is expressed on T and B cells.
11,19 CD27+ B cells
are quickly activated to produce a higher level of immuno-
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Table 4. Mean Percentage of CD27
high Plasma Cells in Peripheral Blood and Serum C-reactive Protein  Levels,
of All Studied Patients 
SLE with flare up SLE with infection Infection HC
(n = 36) (n = 23) (n = 7) (n = 26)
Mean percentage of CD27
high 15.5 ± 1.8*
,� 43.1 ± 6.3* 57.2 ± 6.6* 2.3 ± 0.4
plasma cells (%)
CRP (mg/dL) 0.7 ± 0.3 5.9 ± 1.3
� 6.8 ± 2.6
� 0.1 ± 0.3
HC, healthy control; CRP, C-reactive protein; SLE, systemic lupus erythematosus.
*Percentages of CD27
high plasma cells are significantly higher in three groups (SLE, SLE with infection, non-SLE with infection), when
compared to healthy controls (p< 0.05).
�Mean CRP levels are higher in SLE with infection and non-SLE with infection, when compared to SLE (p< 0.05).
�Mean percentage of CD27
highplasma cells is significantly lower in SLE, when compared to SLE with infection (p< 0.05).
Table 5. The Correlation between the Percentage of CD27
high Plasma Cells and the Marker of Systemic Lupus 
Erythematosus Disease Activity
SLE with flare up SLE with infection
r p r p
SLEDAI 0.866 < 0.001 - 0.422 0.45
Anti-dsDNA 0.886 < 0.001 - 0.074 0.738
C3 - 0.392 0.018 0.041 0.853
C4 - 0.337 0.044 - 0.090 0.689
Anti-Ro 0.575 0.07 0.218 0.604
Anti-La 0.342 0.075 0.056 0.886
Anti-Cardiolipin IgG - 0.206 0.283 - 0.355 0.212
Anti-Cardiolipin IgM - 0.234 0.345 - 0.324 0.213
Anti-RNP 0.30 0.881 - 0.117 0.718
Anti-Sm - 0.08 0.691 0.097 0.764
Rheumaotid factor 0.102 0.751 0.289 0.638
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
Fig. 2.Different expressions of peripheral CD27
highplasma cells in the four patient groups. (A) SLE with pulmonary haemorrhage (18%). (B) SLE with
Streptococcus pneumonia infection (63%). (C) Non-SLE with Staphylococcus aureusinfection (54%). (D) Healthy control (2%). SLE, systemic lupus
erythematosus
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4globulin in comparison to CD27- B cells.
19
Previous studies show that the expansion of CD27
high
plasma cells is associated with the serological presence of
particular autoantibodies, including anti-dsDNA, anti-Ro,
anti-La, anti-Sm, and anti-histone antibodies.
10-12 In our data,
circulating CD27
high plasma cells seem to be important for
the survey of disease activity in SLE patients without infec-
tion, because there is a significant correlation between the
frequency of CD27
high plasma cells in peripheral blood and
disease activity (i.e., SLEDAI, anti-dsDNA, C3 and C4
level, Table 5). However, we cannot use these parameters
to evaluate disease activity in SLE patients with infection,
due to the fact there is no correlation with disease activity
(Table 5). 
In SLE patients with or without infection, a significantly
increased percentage of CD27
high plasma cells from the
peripheral blood can be found from our data (but a signifi-
cantly higher percentage of CD27
high plasma cells in SLE
patients with infection), when compared to healthy con-
trols (Fig. 2). Non-SLE patients with infection also have a
higher percentage of CD27
high plasma cells. Infection is an
important issue in SLE patients, because it is one of the
most frequent causes of death among afflicted individuals.
20
CRP is a traditional serological parameter used to disti-
nguish a lupus flare-up from infection.
13,14 However, no
elevated level of CRP was found in patients with SLE, and
the CRP level can be elevated in a lupus flare-up without
infection.
21,22 For this reason, CRP is not always a good para-
meter to evaluate SLE patients with or without infection.
Novel parameters to differentiate infectious disease from
exacerbation in lupus patients include low soluble Fc
gamma receptor III; elevated granulocyte colony-stimulat-
ing factor; and elevations in sCD14, sICAM-1, or sE-
selectin.
23,24 In our data, there was no significant difference
between SLE patients with infection and non-SLE patients
with infection, in terms of the expansion of peripheral
CD27
high plasma cells. Infection is associated with immune
hyperactivation caused by a triggering of external antigens
and immune responses of SLE with flare-up are activated
by autoantigens. Under either of these two conditions,
hyperactive CD27
high plasma cells increase in number.
Infection should be considered another cause of increase in
CD27
high plasma cells.
12 Plasma cells play a major role to
produce antibody by homing to the bone marrow.
18 During
acute inflammation or infection, transiently elevation of
plasma cells can be found. Therefore, the percentage of
CD27
high plasma cells can not be used to differentiate SLE
patients with infection or non-SLE patients with infection.
From our data, there were increasing plasma cell numbers
in both infection and SLE flares; however, an increased
percentage of CD27
high plasma cells was found in the
infection compared with SLE flares. The mechanism was
still unclear.
Because of their long-term use of immunosuppressive
therapy and persistent hypocomplementaemia, patients
with SLE are at higher risk of contracting common and
opportunistic infections, compared to the general popula-
tion.
25,26 If SLE patients hold the baseline data of the per-
centage of circulating CD27
high plasma cells, we can eval-
uate whether a SLE patient is in an infectious state or not.
Higher percentages of CD27
high plasma cells are found
among SLE patients with infection, and lower percentages
of CD27
high plasma cells (though higher than that in con-
trols) are more prevalent in SLE patients with active di-
sease. In SLE patients with infection, the percentage of
CD27
high plasma cells decreased significantly following
CD27
high Plasma Cells in SLE
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Fig. 3.In an SLE patient with Streptococcus pneumonia infection, after the antibiotics therapy, there was a significant decline in the percentage of
CD27
highplasma cells one month later (33% to 11%). The high level of CRP decreased to normal range (4.2 mg/dL to 0.31 mg/dL). SLE, systemic lupus
erythematosus; CRP, C-reactive protein.
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adequate antibiotics therapy (Fig. 3). 
Various microorganisms-including bacterial, viral, fun-
gal, and protozoa infections-are major causes of morbidity
and mortality in SLE patients with infection.
20,27,28 Timely
antibiotic therapy is required for SLE patients with infection,
but adequate immunosuppression is required for the con-
trol of SLE with flare-up. The percentage of CD27
high
plasma cells provides clues for decision-making vis-à-vis
appropriate therapy, when active lupus cannot be clearly
distinguished from infection.
In summary, the percentage of CD27
high plasma cells
from peripheral blood is a good biomarker for evaluating
disease activity in SLE patients who do not have infection,
and it can also serve as a potential parameter for distingui-
shing a lupus flare-up from infection.
This study was supported by Tri-Service General Hospital
and National Defense Medical Center (Grant no: TSGH-
C99-141).
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